|
CLINT1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.73320024998702E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.98859961620235E-10 |
| Normal-vs-Stage2 |
1.766720E-04 |
| Normal-vs-Stage3 |
6.58350041149447E-10 |
| Normal-vs-Stage4 |
4.33840000002572E-06 |
| Stage1-vs-Stage2 |
4.180200E-01 |
| Stage1-vs-Stage3 |
2.483800E-01 |
| Stage1-vs-Stage4 |
7.945800E-01 |
| Stage2-vs-Stage3 |
1.534560E-01 |
| Stage2-vs-Stage4 |
6.815000E-01 |
| Stage3-vs-Stage4 |
3.183000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.55779944499557E-10 |
| Normal-vs-AfricanAmerican |
9.337600E-03 |
| Normal-vs-Asian |
1.15450000004458E-07 |
| Caucasian-vs-AfricanAmerican |
3.448400E-01 |
| Caucasian-vs-Asian |
8.478200E-01 |
| AfricanAmerican-vs-Asian |
3.585400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.01120001050737E-09 |
| Normal-vs-Female |
6.82950029862184E-10 |
| Male-vs-Female |
9.472600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.24910001523205E-09 |
| Normal-vs-Age(41-60Yrs) |
4.0223000485895E-09 |
| Normal-vs-Age(61-80Yrs) |
4.1499999992034E-08 |
| Normal-vs-Age(81-100Yrs) |
1.527880E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.893600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.017600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.199600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.241400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.676800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.475000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.155400E-01 |
| Classical-VS-Follicular |
3.728800E-01 |
| Classical-VS-Other |
4.967000E-01 |
| Classical-VS-Normal |
6.95539958961433E-10 |
| Tall-VS-Follicular |
4.923200E-01 |
| Tall-VS-Other |
5.958400E-01 |
| Tall-VS-Normal |
1.69318999999613E-05 |
| Follicular-VS-Other |
4.005000E-01 |
| Follicular-VS-Normal |
2.2276999999904E-05 |
| Other-VS-Normal |
2.876200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.27029994803729E-09 |
| Normal-vs-N1 |
1.4375000000344E-06 |
| N0-vs-N1 |
8.977400E-01 |
|
|
